COVID-19 vaccine tracker

TrackersTrackers
| 24 June 2022 | By Jeff Craven 

In March 2020, the Regulatory Focus editorial team was eager to find a way to meet the information needs of RAPS members and the regulatory community as the reality of a coronavirus pandemic set in. Guided by the RAPS Editorial Advisory Committee, the first iteration of this tracker was published on 21 March 2020. 
 
What started as a running list containing one Phase I vaccine candidate (now known as Moderna’s Spikevax) and scores of preclinical possibilities evolved into two sortable spreadsheets rich with clinical evidence, regulatory decisions and distribution plans – all supported by myriad links to original data sources for substantiation and verification. The data has been updated consistently – first weekly, then biweekly – since March 2020.
 
While most parts of the world still sit in public health emergency status, the development and approval of vaccines against SARS-CoV-2 have reached a mature phase. As such, we do not plan to update this tracker after 24 June 2022.
 
Regulatory Focus greatly appreciates the efforts of Jeff Craven, our contributing reporter, who created and updated this chart throughout the pandemic. Many thanks as well to the RAPS IT staff for helping us to refine and improve and usability of the data.
 
This update contains new information on vaccines from Pfizer/BioNTech, Moderna, Gamaleya Research Institute, Janssen Vaccines, Sinopharm, Novavax and Valneva, as well as vaccine candidates from Sanofi/GSK and Bavarian Nordic. If you notice an issue with this data, please email news@raps.org.
 
Denise Fulton
Vice President, Research & Content Strategy
RAPS



Vaccine candidates in development

 

 

Authorized/approved vaccines

 

 

 

COVID-19 vaccine initiatives

OWS: Operation Warp Speed is a collaboration of several US government departments including Health and Human Services (HHS) and subagencies, Defense, Agriculture, Energy and Veterans Affairs and the private sector. OWS has funded JNJ-78436735 (Janssen), mRNA-1273 (Moderna), and NVX‑CoV2373 (Novavax), V590 (Merck/IAVI), V591 (Merck/Themis), AZD1222 (AstraZeneca/University of Oxford), and the candidate developed by Sanofi and GlaxoSmithKline.
 
OWS is “part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.” 
 
ACTIV: Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18 biopharmaceutical companies in an initiative called ACTIV. ACTIV aims to fast-track development of drug and vaccine candidates for COVID-19.
 
COVPN: The COVID-19 Prevention Trials Network (COVPN) combines clinical trial networks funded by the National Institute of Allergy and Infectious Diseases (NIAID): the HIV Vaccine Trials Network (HVTN), HIV Prevention Trials Network (HPTN), Infectious Diseases Clinical Research Consortium (IDCRC), and the AIDS Clinical Trials Group.
 
COVAX: The COVAX initiative, part of the World Health Organization’s (WHO) Access to COVID-19 Tools (ACT) Accelerator, is being spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI); Gavi, the Vaccine Alliance; and WHO. The goal is to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries. CEPI’s candidates from companies Inovio, Moderna, CureVac, Institut Pasteur/Merck/Themis, AstraZeneca/University of Oxford, Novavax, University of Hong Kong, Clover Biopharmaceuticals, and University of Queensland/CSL are part of the COVAX initiative. The US joined COVAX on 21 January. The most up-to-date forecast of COVAX's vaccine supply can be found here. An interim distribution forecast, most recently published 3 February, can be found here.
 

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

5;8;16;